newsfilter
← Latest News
GlobeNewswire·

Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference

  • Orchestra BioMed announced Chairman & CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on Sept. 10, 2026, at 1:30pm ET.
  • Hochman will host one-on-one investor meetings on Sept. 9 & 10, 2026.
  • A live webcast of the presentation will be available via the company's Investor Relations website with a replay option.
  • The company's flagship AVIM Therapy is a bioelectronic hypertension treatment in pivotal trials with Medtronic, featuring FDA Breakthrough Device Designations.
  • AVIM Therapy targets uncontrolled hypertension in pacemaker-indicated patients, representing an estimated 7.7 million U.S. patients.
  • The second flagship candidate, Virtue SAB, is a non-coated drug delivery balloon system in trials for atherosclerotic artery disease.
  • Virtue SAB holds FDA Breakthrough Device Designations for coronary in-stent restenosis, coronary small vessel disease, & below-the-knee peripheral artery disease.